You have counted the calories, held the diet and kept the gym going, and the weight has not moved. Somewhere in the search for why, the suggestion arrives that the answer is in your blood, and that a panel of tests will find the barrier that discipline could not.

Part of that is true. Measurement genuinely beats guesswork, and there are metabolic conditions that change what a deficit does. The rest of it (the promise that a lab report explains a stalled weight and hands back a personalised plan) is sold with more confidence than the tests themselves carry. Here is which parts hold.

• A metabolic workup is a set of measurements read against a history, not a diagnostic engine. No single line on a report carries the explanation on its own.
• Fasting insulin and HOMA-IR are not endorsed for routine clinical use by the ADA, EASD or RSSDI. Indian cut-offs range from 1.23 to 3.6 across cohorts and none has been outcome-validated.
• Insulin assays are not harmonised between labs. A fasting insulin result from one lab is not reliably comparable to one from another lab.
• BMI is a reasonable trigger to look further, not a description of a specific body. The more common Indian problem is a person inside the normal BMI range carrying enough visceral fat to have poor metabolic markers.
• Thyroid, lipid and cortisol tests have real clinical uses. None of them was validated to explain a stalled weight.
• The test for whether an investigation was worth doing is simple: did the result change a decision?

A metabolic workup is a set of measurements taken together and read against a history, not a diagnostic engine. In practice that usually means glucose-based blood tests, a body-composition or anthropometric assessment, and a clinical history covering medications, sleep, previous dieting and any existing diagnosis.

Its value comes from the combination. No single line on the report carries the explanation on its own, and a clinician reading it is weighing all of it against what you have told them in the room.

That framing matters because it sets what the report can reasonably be asked for:

• Confirming or excluding a condition that changes management: realistic.
• Producing a number that tells you why last year did not work: not realistic.

The distinction is worth insisting on, because a workup sold as the second thing tends to end in more tests rather than fewer, each one ordered to explain the last, and none of them answering the question that prompted the first.

Fasting insulin and HOMA-IR are the tests most often placed at the centre of a lab-led weight-loss pitch, and they are the two with the weakest formal standing. Neither the American Diabetes Association nor the European Association for the Study of Diabetes endorses HOMA-IR for routine clinical use.

India's position is the same, expressed by omission. RSSDI's clinical practice recommendations define diabetes and prediabetes using fasting plasma glucose, the two-hour oral glucose tolerance test and HbA1c. Fasting insulin and HOMA-IR do not appear among the diagnostic criteria at all.

The Oxford unit that developed the HOMA model states there is no absolute value for its indices, because results depend on the specific assays used for glucose, insulin and C-peptide. It declines to publish universal thresholds.

Indian-derived cut-offs exist but do not converge:

• Published figures run from 1.23 to 3.6 across different cohorts and derivation methods.
• None has been validated against progression to diabetes or against the clamp reference method.
• A 2024 analysis of 5,578 people found that adding HOMA-IR to prediction models already using HbA1c and fasting glucose did not materially improve them.

None of that makes the tests useless. It makes them research instruments that inform a clinician's thinking, rather than numbers a reader can grade themselves against.

The most attractive claim in the lab-led pitch is that repeat testing tracks progress, so improvement becomes visible in the numbers rather than only on the scale. For insulin that claim needs a large qualification.

Insulin immunoassays are not harmonised to a single reference method, and work on insulin standardisation has documented substantial disagreement between commercial platforms measuring the same sample, with no internationally listed reference method yet in place.

The practical consequence:

• A fasting insulin or HOMA-IR result from one lab is not reliably comparable with one from another lab.
• Indian labs do not routinely disclose which platform produced a given number.
• If a marker is going to be re-tested, use the same lab each time and tell the clinician you did so. That is the difference between a comparison and a coincidence.

HbA1c and fasting glucose travel between labs far better, which is one practical reason they, rather than insulin, sit in the guidelines.

BMI's weakness is well known and often overstated in the wrong direction. It does not distinguish muscle from fat, so a heavily trained person can be classified as overweight with low body fat. The more common Indian problem runs the other way: a person inside the normal BMI range carrying enough visceral fat to have poor metabolic markers.

That pattern (thin outside and fat inside) is a recognised South Asian phenotype. It is why Indian and South Asian criteria set the overweight threshold at a BMI of 23 and obesity at 25 kg/m², lower than the international figures.

What BMI does well is population screening, cheaply and repeatably. It is a poor description of one body and a reasonable trigger to look further, which is the job it should be given.

Three claims recur in this space and should be treated more carefully than they usually are.

Thyroid function is the strongest of the three. Hypothyroidism is a real, testable condition with a defined treatment, and thyroid tests are ordered for good reason.

A lipid profile sits in the middle. It is a cardiovascular risk measurement, worth having and worth acting on, but not a reading of why fat loss has stalled.

Cortisol is the weakest. Cortisol testing has established clinical uses in diagnosing specific endocrine disorders. It is not part of any endorsed metabolic-screening criteria, and no routine cortisol measurement has been validated as a test for stress-related weight gain or for a plateau.

What these three have in common is worth naming. Each is a real test with a real clinical use. In each case, the use it is being borrowed for is not the one it was validated against.

A test that answers a different question well is still answering a different question, and a report full of them does not add up to an explanation for a stalled weight.

Stated plainly: a metabolic report can confirm or exclude conditions that change what happens next. It cannot itemise the reasons a year of effort produced no result, and a plan built on the promise that it can is overselling the paperwork.

The case for testing is strongest when something in the picture does not fit. That usually means one of these situations:

• Weight that climbs without a change in intake.
• Symptoms alongside the weight.
• A family history of early diabetes.
• A plateau that has held through several honest attempts.

In those situations a report changes decisions, which is the only real test of whether an investigation was worth doing.

Some of the tests discussed here can be self-booked in India without a prescription as of 2026, which makes ordering them easy and interpreting them no easier. What separates a useful workup from an expensive one is having a registered medical practitioner decide which tests to order and read the results against your history.

Weight that has not moved despite genuine effort, and not sure which tests are actually worth ordering? A Voy clinician can assess what the picture needs rather than defaulting to a standard panel. Book an assessment.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.